Quadri-Positive Stromal Cells for PolyQ Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for polyglutamine (polyQ) diseases, such as spinocerebellar ataxias, lack an effective medical solution, leading to progressive neuronal degeneration and fatal outcomes.
Innovation Solution
Administering mesenchymal stem cells, specifically quadri-positive stromal cells (QPSCs), via parenteral or local routes, in multiple dosages over two to six weeks to treat polyQ diseases, including spinocerebellar ataxias, Machado-Joseph disease, and Huntington's disease, with the cells showing immunomodulatory and neuroprotective effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medical treatments are used for polyQ diseases, then treatment protocols are established, but no effective therapeutic solution is achieved and neuronal degeneration progresses
Solution Approach 1:
The patent uses stem cells as an intermediary therapeutic agent that mediates between the patient's deteriorating neuronal tissue and the need for regeneration. The stem cells differentiate into neuron-like cells and secrete neurotrophic factors, acting as a bridge to restore damaged neural pathways and combat polyQ disease progression.
Solution Approach 2:
The patent employs multiple dosing cycles with varying cell quantities (e.g., 1×10^6 to 1×10^8 cells per injection) and dosing intervals (2-6 weeks) to optimize therapeutic effect. This parameter optimization ensures sufficient stem cell engraftment and neurotrophic factor secretion while minimizing potential adverse effects.
2Reliability
If stem cells are administered in single dosage, then treatment simplicity is maintained, but therapeutic effect is insufficient for progressive neurodegenerative disease
Solution Approach 1:
The patent divides the stem cell treatment into multiple discrete dosing cycles, with each cycle consisting of 1-5 injections administered at 2-6 week intervals. This segmentation allows the therapeutic effect to be built progressively, with each dose contributing to stem cell engraftment and neurotrophic factor accumulation in the target tissue.
Solution Approach 2:
The treatment protocol employs periodic administration of stem cells at scheduled intervals (2-6 weeks between doses) to maintain therapeutic effect. This periodic action ensures continuous supply of neurotrophic factors and prevents disease progression while allowing time for stem cell differentiation and integration between doses.
3Reliability
If high quantity of stem cells is administered, then therapeutic potential is enhanced, but risk of adverse effects increases
Solution Approach 1:
The patent administers stem cells at quantities that are sufficient to achieve therapeutic effect (1×10^6 to 1×10^8 cells per injection) without excessive dosing that would increase adverse effects. The multiple dosing approach allows cumulative therapeutic benefit while keeping each individual dose within safe parameters.
Solution Approach 2:
The patent includes pre-treatment steps such as immunosuppression therapy before stem cell administration to prevent rejection and reduce adverse effects. This preliminary action prepares the patient's immune system to tolerate the transplanted stem cells, enabling higher cell doses to be administered safely.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stem cell treatment significantly improves motor function, prevents body weight loss, and reduces oxidative stress in polyQ disease models, demonstrating therapeutic potential by differentiating into neuron-like cells and secreting neurotrophic factors.
Implementation Method 1
demonstrating therapeutic potential by differentiating into neuron-like cells
Implementation Method 2
secreting neurotrophic factors
Implementation Method 3
showing immunomodulatory and neuroprotective effects
Implementation Method 4
reduces oxidative stress in polyQ disease models
Data Source
AI summary
Provided are methods and articles of manufacture for use in stem cell therapy, for the treatment of diseases or conditions of SCA. Particularly, the invention provides a method for treating SCA, comprising parenterally or locally administering an effective amount of stem cells as a unit dosage to a subject, wherein the administration is performed with one or more treatment cycles, wherein one treatment cycle comprises dosing three unit dosages each at a dosing interval of two to six weeks.